

SUPPLEMENTARY APPENDICES

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

Authors:

Noman Paracha, Adriana Reyes, Véronique Diéras, Ian Krop, Xavier Pivot, Ander Urruticoechea

Corresponding author:

Noman Paracha

F. Hoffmann-La Roche AG

Grenzacherstrasse 124


4070 Basel

Switzerland

Tel: +41 61 688 2661

Email: noman.paracha@roche.com

Online Resource 6: Appendix 6. Treatment network plots for adverse events: (a) adverse events (grade 3 and above); (b) treatment discontinuation due to adverse events; (c) serious adverse events; (d) diarrhea, neutropenia, increased ALT; (e) fatigue, nausea, vomiting; (f) increased AST



ALT alanine aminotransferase, *AST* aspartate aminotransferase, *Cap* capecitabine, *Lap* lapatinib, *Per* pertuzumab, *T-DM1* trastuzumab emtansine, *Tras* trastuzumab